Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
Fiche publication
Date publication
mars 2019
Journal
Gut
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Pr PESSAUX Patrick, Dr CROUCHET Emilie, Dr VERRIER Eloi
Tous les auteurs :
Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF
Lien Pubmed
Résumé
Hepatitis D virus (HDV) is a circular RNA virus coinfecting hepatocytes with hepatitis B virus. Chronic hepatitis D results in severe liver disease and an increased risk of liver cancer. Efficient therapeutic approaches against HDV are absent.
Mots clés
antiviral therapy, hepatitis D, liver, screening
Référence
Gut. 2019 Mar 4;: